TRAIL Trimer Construct for Mesothelin-Positive Cancer Apoptosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current TRAIL-based therapies for cancer are ineffective in directly inducing apoptosis in mesothelin-positive cells, often relying on bystander mechanisms that protect rather than eliminate the target cells.
Innovation Solution
A construct comprising a TNF-related apoptosis-inducing ligand (TRAIL) trimer with three extracellular TRAIL domains fused in a head-to-tail configuration, combined with an epitope binding agent that competitively inhibits binding to cell surface human mesothelin, specifically targeting and inducing apoptosis in mesothelin-positive cells expressing death receptors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If TRAIL-based therapies are used to target mesothelin-positive cells, then cancer cells can be eliminated, but bystander mechanisms protect target cells from apoptosis
Solution Approach 1:
The TRAIL molecule is segmented into three separate extracellular domains (D1, D2, D3) that are fused in a head-to-tail configuration. This segmentation allows each domain to independently interact with death receptors, ensuring that at least one functional domain remains available to induce apoptosis even when others are occupied by mesothelin binding, thereby overcoming the bystander protection mechanism
Solution Approach 2:
The patent combines multiple functional elements into a single chimeric protein: mesothelin-binding capability (from the antibody fragment), TRAIL apoptosis-inducing activity (from the three fused domains), and controlled spatial arrangement (through linkers). This merging creates a unified therapeutic agent that simultaneously targets mesothelin-positive cells and induces direct apoptosis while minimizing bystander effects
2Reliability
If epitope binding agent is added to achieve specific targeting, then tumor site enrichment is improved, but binding competition with P4-TR3 or HN1-TR3 occurs
Solution Approach 1:
The chimeric protein dynamically switches between two functional states: (1) mesothelin binding mode, where the antibody fragment binds to mesothelin on target cells, and (2) death receptor engagement mode, where the TRAIL domains bind to DR4 or DR5. This dynamic functionality allows the single molecule to adapt its binding partner based on spatial context, eliminating the need for separate targeting and killing components that would compete for binding
3Reliability
If TRAIL domains are fused in head-to-tail configuration, then killing capacity is retained, but structural complexity increases
Solution Approach 1:
The TRAIL molecule is divided into three extracellular domains (D1, D2, D3) that are sequentially fused in a head-to-tail configuration. This segmentation preserves the functional integrity of each domain while creating a linear structure that is simpler to design and produce than multi-subunit complexes, as the domains are connected by flexible linkers rather than requiring separate protein-protein interactions
Solution Approach 2:
The patent modifies the structural parameters of TRAIL by fusing only the three extracellular domains while excluding the transmembrane and intracellular domains. This parameter change creates a soluble fusion protein with optimized properties for therapeutic use, retaining apoptosis-inducing capability while improving solubility, stability, and ease of production compared to full-length TRAIL
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The construct effectively induces apoptosis in mesothelin-positive cancer cells while minimizing bystander cell death, demonstrating enhanced specificity and efficacy in cancer treatment.
Implementation Method 1
The construct effectively induces apoptosis in mesothelin-positive cancer cells while minimizing bystander cell death
Implementation Method 2
an epitope binding agent, wherein the epitope binding agent competitively inhibits binding of P4 or HN1 to cell surface human mesothelin
Data Source
AI summary
The present disclosure provides constructs that comprise (a) a TNF-related apoptosis-inducing ligand (TRAIL) trimer comprising three consecutive extracellular TRAIL domains fused together in a head-to-tail configuration; (b) an epitope binding agent, and (c) optionally one or more additional components, wherein the epitope binding agent competitively inhibits binding of P4-TR3 or HN1-TR3 to cell surface human mesothelin. Constructs of the present disclosure induce apoptosis in cells expressing human mesothelin and a death receptor (DR4 or DR5) on the cell's surface.